omniture

Sky News, Helen Dalley interviews Dr Graham Kelly

2015-03-10 12:28 1732

SYDNEY, March 10, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN') CEO, Dr Graham Kelly, PhD, was interviewed by Sky News', Helen Dalley about the breakthrough brain cancer drug being developed by Novogen. Novogen is an Australian-US drug discovery company focused on the clinical development of drugs targeting two novel drug targets pertinent to a range of therapeutic indications.

The interview can be viewed at http://goo.gl/PH737R.

About Novogen Limited

Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN').  The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our website: www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

Source: Novogen Ltd
Related Links:
collection